Nuvectis PharmaNVCT
About: Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
Employees: 13
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
333% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 3
181% more capital invested
Capital invested by funds: $7.15M [Q4 2024] → $20M (+$12.9M) [Q1 2025]
45% more call options, than puts
Call options by funds: $1.3M | Put options by funds: $895K
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
6% more funds holding
Funds holding: 31 [Q4 2024] → 33 (+2) [Q1 2025]
1.92% more ownership
Funds ownership: 6.84% [Q4 2024] → 8.75% (+1.92%) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
HC Wainwright & Co. Joseph Pantginis | 48%upside $15 | Buy Reiterated | 30 Apr 2025 |
Maxim Group Naz Rahman | 68%upside $17 | Buy Initiated | 2 Apr 2025 |
Laidlaw & Co. Yale Jen | 88%upside $19 | Buy Initiated | 17 Mar 2025 |
Financial journalist opinion
Based on 4 articles about NVCT published over the past 30 days









